Heart failure less likely to be diagnosed in primary care

GPs need better access to diagnostic tests Related items fromOnMedica Test could tackle underdiagnosis of MI in women Hospitals fail women with myocardial infarction Oxygen therapy after heart attack does not prevent heart failure New ‘treadmill test’ can predict mortality Women less likely than men to achieve CHD targets
Source: OnMedica Latest News - Category: UK Health Source Type: news

Related Links:

ConclusionsA different role for the AGE-RAGE axis was observed in HF and ACS. All the sRAGE forms were directly related with glycation parameters in HF, but not in ACS. The independent value of the sRAGE forms on each cardiovascular disease was supported by esRAGE being an independent predictor of bad long-term prognosis only for HF.
Source: Nutrition, Metabolism and Cardiovascular Diseases - Category: Nutrition Source Type: research
Publication date: Available online 21 June 2019Source: Canadian Journal of CardiologyAuthor(s): Mark Canney, Mila Tang, Lee Er, Sean J. Barbour, Ognjenka Djurdjev, Adeera Levin, CanPREDDICT InvestigatorsAbstractBackgroundUsing standard cut-offs derived from healthy adults, high-sensitivity cardiac troponin T (hs-cTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) are frequently elevated in patients with reduced glomerular filtration rate (GFR), with unclear implications. We sought to compare GFR-specific cut-offs of each biomarker to standard cut-offs for discrimination of cardiovascular risk in asymptomatic pa...
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research
ConclusionExogenous treatment of PGE2 and the EP4 receptor agonist blocked the pro-inflammatory actions of LPS. Mechanistically, this was mediated via reduced Akt phosphorylation and inhibition of NF-κB.
Source: Prostaglandins and Other Lipid Mediators - Category: Lipidology Source Type: research
ConclusionsTo reduce unplanned 30-day readmission more effectively, discharge planning should include post-discharge services to address health conditions beyond the primary cause of the IH.
Source: Journal of General Internal Medicine - Category: Internal Medicine Source Type: research
CONCLUSIONS: These data suggested that meflin is involved in cardiac tissue repair after injury and has an inhibitory role in MF differentiation of cardiac fibroblastic cells and the development of cardiac fibrosis. PMID: 31221024 [PubMed - as supplied by publisher]
Source: Circulation Research - Category: Cardiology Authors: Tags: Circ Res Source Type: research
Conclusions: The mFI-5 is an independent predictor of postoperative morbidity and mortality in elderly patients undergoing surgery for hip fractures. This clinical tool can be used by hospitals and surgeons to identify high-risk patients, accurately council patients and families with transparency, and guide perioperative care to optimize patient outcomes. Level of Evidence: Prognostic Level III. See Instructions for Authors for a complete description of levels of evidence.
Source: Journal of Orthopaedic Trauma - Category: Orthopaedics Tags: Original Article Source Type: research
Natriuretic peptide [NP; B ‐type NP (BNP), N‐terminal proBNP (NT‐proBNP), and midregional proANP (MR‐proANP)] concentrations are quantitative plasma biomarkers for the presence and severity of haemodynamic cardiac stress and heart failure (HF). End‐diastolic wall stress, intracardiac filling pressures, and intracard iac volumes seem to be the dominant triggers. This paper details the most important indications for NPs and highlights 11 key principles underlying their clinical use shown below. NPs should always be used in conjunction with all other clinical information. NPs are reasonable surrogates for intracar d...
Source: European Journal of Heart Failure - Category: Cardiology Authors: Tags: Position Paper Source Type: research
CHELMSFORD, Mass.--(BUSINESS WIRE)--Jun 18, 2019--ZOLL ®  Medical Corporation, an Asahi Kasei Group Company that manufactures medical devices and related software solutions, today announced it has acquired TherOx, Inc., of Irvine, Calif., a privately held company. TherOx is focused on improving treatment of acute myocardial infarction (AMI) and markets systems to deliver SuperSaturated Oxygen (SSO 2 ) Therapy. SSO 2 Therapy, which was recently approved by the Federal Drug Administration (FDA), has been demonstrated to reduce infarct size after primary coronary intervention (PCI) with stenting in patients wi...
Source: JEMS: Journal of Emergency Medical Services News - Category: Emergency Medicine Tags: News Industry News Source Type: news
Myocardial infarction (MI), via change of either the structure and/or the functioning, is a common cause of the heart failure [1]. The main characteristic of MI-induced heart failure is reduced ejection fraction (HFrEF). The current first line treatment strategy (long-duration pharmacologic therapy) carries adverse remodeling risks [2,3]. Newer strategies reducing recurrent adverse remodeling as well as reinforce cardiac resynchronization are needed.
Source: International Journal of Cardiology - Category: Cardiology Authors: Tags: Editorial Source Type: research
Fresh off receiving a PMA, TherOx is now in the process of being acquired by Zoll Medical, an Asahi Kasei Group Company.  Additional terms of the deal were not disclosed. Irvine, CA-based TherOX is focused on improving the treatment of acute myocardial infarction, and markets systems to deliver SuperSaturated Oxygen (SSO2) Therapy. The therapy has been demonstrated to reduce infarct size after primary coronary intervention (PCI) with stenting in patients with left anterior descending ST-elevation myocardial infarction. When a large ischemic area of muscle damage remains following AMI, the patient condition oft...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news
More News: Cardiology | Heart | Heart Attack | Heart Failure | Hospitals | Primary Care | UK Health | Women